Table 1.
Clinical and demographic characteristics of included patients
| Southwest (N = 132) | Midwest (N = 54) | Southeast (N = 64) | Total (N = 250) | |
| Sex | ||||
| Male, n (%) | 78 (59.1) | 28 (51.9) | 34 (53.1) | 140 (56.0) |
| Female | 54 (40.9) | 26 (48.1) | 30 (46.9) | 110 (44.0) |
| Age | ||||
| Mean (SD) | 64.9 (8.8) | 65.6 (8.1) | 64.6 (9.2) | 65.0 (8.7) |
| Median | 67.0 | 66.5 | 66.0 | 66.5 |
| Range | 38.0–80.0 | 44.0–79.0 | 40.0–80.0 | 38.0–80.0 |
| Race (grouped) | ||||
| White | 107 (81.1%) | 53 (98.1%) | 49 (76.6%) | 209 (83.6%) |
| Hispanic/Latino | 13 (9.8%) | 0 (0.0%) | 4 (6.2%) | 17 (6.8%) |
| Black/African American | 4 (3.0%) | 1 (1.9%) | 8 (12.5%) | 13 (5.2%) |
| Asian | 3 (2.3%) | 0 (0.0%) | 1 (1.6%) | 4 (1.6%) |
| American Indian/Alaskan Native | 4 (3.0%) | 0 (0.0%) | 0 (0.0%) | 4 (1.6%) |
| Native Hawaiian/Pacific Islander | 1 (0.8%) | 0 (0.0%) | 1 (1.6%) | 2 (0.8%) |
| Other | 0 (0.0%) | 0 (0.0%) | 1 (1.6%) | 1 (0.4%) |
| Ethnicity (dichotomized) | ||||
| Hispanic/Latino | 13 (9.8%) | 0 (0.0%) | 4 (6.2%) | 17 (6.8%) |
| Non-Hispanic | 119 (90.2%) | 54 (100.0%) | 60 (93.8%) | 233 (93.2%) |
| Smoking | ||||
| Yes | 59 (44.7%) | 27 (50.0%) | 25 (39.1%) | 111 (44.4%) |
| No | 73 (55.3%) | 27 (50.0%) | 39 (60.9%) | 139 (55.6%) |
| BMI > 30 kg/m2 | ||||
| Yes | 14 (10.6%) | 5 (9.4%) | 14 (21.9%) | 33 (13.3%) |
| No | 118 (89.4%) | 49 (90.6%) | 50 (78.1%) | 217 (86.7%) |
| Diabetes mellitus | ||||
| Yes | 38 (28.8%) | 9 (16.7%) | 23 (35.9%) | 70 (28.0%) |
| No | 94 (71.2%) | 45 (83.3%) | 41 (64.1%) | 180 (72.0%) |
| Hypertension | ||||
| Yes | 47 (35.6%) | 20 (37.0%) | 30 (46.9%) | 97 (38.8%) |
| No | 85 (64.4%) | 34 (63.0%) | 34 (53.1%) | 153 (61.2%) |
| Germline result | ||||
| Positive | 19 (14.4%) | 6 (11.1%) | 13 (20.3%) | 38 (15.2%) |
| Negative | 55 (41.7%) | 24 (44.4%) | 22 (34.4%) | 101 (40.4%) |
| VUS | 58 (43.9%) | 24 (44.4%) | 29 (45.3%) | 111 (44.4%) |
| Result (dichotomized) | ||||
| Positive | 19 (14.4%) | 6 (11.1%) | 13 (20.3%) | 38 (15.2%) |
| VUS/negative | 113 (85.6%) | 48 (88.9%) | 51 (79.7%) | 212 (84.8%) |
| Pedigree complete | ||||
| Yes | 67 (50.8%) | 24 (44.4%) | 33 (51.6%) | 124 (49.6%) |
| No | 65 (49.2%) | 30 (55.6%) | 31 (48.4%) | 126 (50.4%) |
| Family history of cancer (any) in first-degree relatives | ||||
| Yes | 47 (35.6%) | 21 (38.9%) | 23 (35.9%) | 91 (36.4%) |
| No | 20 (15.2%) | 3 (5.6%) | 10 (15.6%) | 33 (13.2%) |
| Family history of pancreatic cancer in first-degree relative | ||||
| Yes | 10 (14.9%) | 5 (20.8%) | 2 (6.1%) | 17 (13.7%) |
| No | 57 (85.1%) | 19 (79.2%) | 31 (93.9%) | 107 (86.3%) |
| Staging AJCC 8th edition at diagnosis (clinical stage) | ||||
| 1 | 18 (13.6%) | 13 (24.1%) | 5 (7.8%) | 36 (14.4%) |
| 2 | 27 (20.5%) | 10 (18.5%) | 13 (20.3%) | 50 (20.0%) |
| 3 | 33 (25.0%) | 9 (16.7%) | 20 (31.2%) | 62 (24.8%) |
| 4 | 54 (40.9%) | 22 (40.7%) | 26 (40.6%) | 102 (40.8%) |
| Staging AJCC 8th edition (early vs late) | ||||
| Early stage (0–2) | 45 (34.1%) | 23 (42.6%) | 18 (28.1%) | 86 (34.4%) |
| Late stage (3–4) | 87 (65.9%) | 31 (57.4%) | 46 (71.9%) | 164 (65.6%) |
| Location | ||||
| Head | 87 (65.9%) | 35 (64.8%) | 45 (70.3%) | 167 (66.8%) |
| Body | 29 (22.0%) | 9 (16.7%) | 6 (9.4%) | 44 (17.6%) |
| Tail | 16 (12.1%) | 10 (18.5%) | 13 (20.3%) | 39 (15.6%) |
| CA 19-9 | ||||
| >37 | 90 (73.2%) | 40 (75.5%) | 45 (70.3%) | 175 (72.9%) |
| ≤37 | 33 (26.8%) | 13 (24.5%) | 19 (29.7%) | 65 (27.1%) |
| Missing | 9 | 1 | 0 | 10 |
| CA 19-9 | ||||
| >300 | 52 (42.3%) | 23 (43.4%) | 31 (48.4%) | 106 (44.2%) |
| ≤300 | 71 (57.7%) | 30 (56.6%) | 33 (51.6%) | 134 (55.8%) |
| Missing | 9 | 1 | 0 | 10 |
| Deceased | ||||
| Yes | 58 (43.9%) | 11 (20.4%) | 23 (35.9%) | 92 (36.8%) |
| No | 74 (56.1%) | 43 (79.6%) | 41 (64.1%) | 158 (63.2%) |
AJCC, American Joint Committee on Cancer; BMI, body mass index; CA 19-9, carbohydrate antigen; VUS, variant of uncertain significance.